share_log

Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)

Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)

深入分析傳奇生物股票:分析師觀點(10條評級)
Benzinga ·  12/10 21:00
10 analysts have expressed a variety of opinions on Legend Biotech (NASDAQ:LEGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在過去的一個季度中,10位分析師對傳奇生物(納斯達克:LEGN)發表了多種觀點,提供了從看好到看淡的多樣化意見。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
總結他們最近的評估,下面的表格顯示了過去30天裏情緒的變化,並將其與之前的月份進行了比較。
Analysts have recently evaluated Legend Biotech and provided 12-month price targets. The average target is $79.2, accompanied by a high estimate of $86.00 and a low estimate of $73.00. This current average reflects an increase of 0.97% from the previous average price target of $78.44.
分析師最近對傳奇生物進行了評估,並提供了12個月的價格目標。平均目標爲79.2美元,最高估計爲86.00美元,最低估計爲73.00美元。目前的平均目標較之前的78.44美元的平均價格目標增加了0.97%。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級:詳細剖析
The standing of Legend Biotech among...
通過對近期分...

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論